Clinical trials: Gram Negative Septic Shock

Sepsis

GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults

• Completed
• Age: 18 years and older
• Phase 2
• Injection or infusion
• Results posted

The primary objective is to estimate the size of the GR270773 treatment effect on 28-day all-cause mortality for two doses of GR270773 versus placebo in adult subjects with suspected or confirmed Gram-negative severe sepsis.

Trial name

NCT00089986

Testing

Intravenous GR270773- Phospholipid Emulsion

Where

390 sites in United States, Argentina and 32 more

Volunteers

1,415 people

Sponsor

GlaxoSmithKline